Yahoo Finance Novo Nordisk to invest $4.1B in NC facility for GLP-1 drugs
Novo Nordisk (NVO) plans to invest $4.1 billion in building out a manufacturing facility in Clayton, North Carolina for its GLP-1 weight-loss drugs Wegovy and Ozempic. This investment is happening a week after Eli Lilly (LLY) unveiled its new factory in Concord, North Carolina.
Yahoo Finance Health Reporter Anjalee Khemlani breaks down the details.
For more expert insight and the latest market action, click here to watch this full episode of Market Domination.
This post was written by Luke Carberry Mogan.
Video transcript
Moving on.
No, no announcing it will spend $4.1 billion building out a new facility in North Carolina to increase the output of its weight loss drug y finances, Angeli Kamlani joins us with more on.
That's right.
No surprise here, Novo node adding to the capacity that it needs for those injectable G LP one drugs that's will go and Oz and it's doing it at the same time that Eli Lilly is.
We know Lily also just recently did the rubber cutting for its new facility, 1 million plus square feet in North Carolina adding to the injectable output.
Now.
No, no saying that this is a 4.1 billion investment for 1.4 million square feet.
Part of its goal to expand capacity by $6.9 billion of investment and is an increase from last year of $3.9 billion.
This will double the company's existing production capacity in North Carolina alone and in the US and then Senator Bernie Sanders today coming out swinging a little bit against Novo Norik over the pricing of the company's drugs.
That's right.
And finally a date set on that, we had heard that Senator Bernie Sanders was looking to subpoena the CEO, but he has now agreed to voluntarily testify on September 24th about the difference in pricing in the US and elsewhere.
